Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort
Talha Munir(St James's University Hospital), Paolo Ghia(Vita-Salute San Raffaele University), Adriana Scheliga(Instituto de Oncologia do Paraná), Oliver Miles(Musgrove Park Hospital), Sowmya Srikanthan(Johnson & Johnson (United States)), Ping Xu(Beijing Proteome Research Center), Mohamed Fouad(Johnson & Johnson (United States)), Danielle Leão(Beneficência Portuguesa de São Paulo), Claire Kavanagh(Johnson & Johnson (Ireland)), Boo Messahel(Royal Marsden NHS Foundation Trust), Christoph Tapprich(Johnson & Johnson (Germany))
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630